Functional Tumor Volume by Fast Dynamic<scp>Contrast‐Enhanced MRI</scp>for Predicting Neoadjuvant Systemic Therapy Response in<scp>Triple‐Negative</scp>Breast Cancer
Benjamin C. Musall(Henry Ford Health System), Jingfei Ma(The University of Texas MD Anderson Cancer Center), Gaiane M. Rauch(The University of Texas MD Anderson Cancer Center), Peng Wei(Creighton University), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Jason B. White(The University of Texas MD Anderson Cancer Center), Elsa Arribas(The University of Texas MD Anderson Cancer Center), Rania M. Mohamed(The University of Texas MD Anderson Cancer Center), Jessica W. T. Leung(The University of Texas MD Anderson Cancer Center), Deanna L. Lane(The University of Texas MD Anderson Cancer Center), Jong Bum Son(The University of Texas MD Anderson Cancer Center), Jia Sun(Nanjing University of Chinese Medicine), Rosalind P. Candelaria(The University of Texas MD Anderson Cancer Center), Beatriz E. Adrada(The University of Texas MD Anderson Cancer Center), Nabil Elshafeey(The University of Texas MD Anderson Cancer Center), Huong T. Le‐Petross(The University of Texas MD Anderson Cancer Center), Wei Yang(Shanghai Jiao Tong University), Elizabeth E. Ravenberg(Eli Lilly (United States)), Medine Böge(The University of Texas MD Anderson Cancer Center), David Spak(The University of Texas MD Anderson Cancer Center), Shu Zhang(Healthwise), Stacy Moulder(The University of Texas MD Anderson Cancer Center), Mark D. Pagel(University of Wisconsin–Madison), Hagar S. Mahmoud(The University of Texas MD Anderson Cancer Center), Alastair M. Thompson(Baylor College of Medicine), Abeer H. Abdelhafez(The University of Texas MD Anderson Cancer Center), Ken‐Pin Hwang(The University of Texas MD Anderson Cancer Center), Senthil Damodaran(The University of Texas MD Anderson Cancer Center)
Cited by 30
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Breast Cancer Before Age 40 Years
|Seminars in Oncology|2009|795
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2016|660